Adherence and Acceptability of Once Daily Lamivudine and Abacavir in Human Immunodeficiency Virus Type-1 Infected Children

Background: Data on adherence to and acceptability of once daily lamivudine and abacavir are few. Methods: Twenty-four U.K. human immunodeficiency virus type-1 infected children 2–13 years of age participated in the Pediatric European Network for the Treatment of AIDS (PENTA) 13 single arm, open label pharmacokinetic study of twice (every 12 hours) versus once (every 24 hours) daily lamivudine and abacavir. Caregivers were asked to complete an adherence questionnaire at screening, week 0 (switch once daily to twice daily) and weeks 4, 12 and 24. Acceptability was also assessed at screening and week 24. Results: Fifteen children were taking lamivudine and abacavir as part of their regimens, 8 lamivudine only and 1 abacavir only. After switching to lamivudine/abacavir every 24 hours, 7 (29%) received once daily regimens for all drugs. Twenty-three (96%) caregivers thought that switching to once daily lamivudine/abacavir would make things a lot/a little easier for their child: 17 (71%) thought it was actually easier after switching. Six mothers with children taking a mixture of twice/once daily drugs changed their mind, whereas all mothers of children on once daily regimens agreed that it was a lot easier. Nonadherence (missing doses in the last 3 days) was reported for 8 of 118 (7%) completed questionnaires; missed doses were reported for every drug in the regimen with reasons such as “not at home,” “forgot” or “routine different from normal.” However, viral loads in all these children remained <100 copies/mL. Conclusion: Adherence to once daily abacavir/lamivudine was good with no evidence of an association between nonadherence and virologic rebound. Acceptability of once daily drugs was best when the whole regimen was dosed once daily.

[1]  P. Cahn,et al.  Abacavir Once or Twice Daily Combined With Once-Daily Lamivudine and Efavirenz for the Treatment of Antiretroviral-Naive HIV-Infected Adults: Results of the Ziagen Once Daily in Antiretroviral Combination Study , 2005, Journal of acquired immune deficiency syndromes.

[2]  S. Khoo,et al.  Plasma Pharmacokinetics of Once- versus Twice-Daily Lamivudine and Abacavir: Simplification of Combination Treatment in HIV-1-Infected Children (Penta-13) , 2005, Antiviral therapy.

[3]  M. Bassetti,et al.  Treatment of HIV infection in children , 2005 .

[4]  J. Tolson,et al.  Perspectives on Adherence and Simplicity for HIV-Infected Patients on Antiretroviral Therapy: Self-Report of the Relative Importance of Multiple Attributes of Highly Active Antiretroviral Therapy (HAART) Regimens in Predicting Adherence , 2004, Journal of acquired immune deficiency syndromes.

[5]  R. McKinney,et al.  Newer treatments for HIV in children , 2004, Current opinion in pediatrics.

[6]  M. Sharland,et al.  Decline in mortality, AIDS, and hospital admissions in perinatally HIV-1 infected children in the United Kingdom and Ireland , 2003, BMJ : British Medical Journal.

[7]  G. Moyle.  The Assessing Patients’ Preferred Treatments (APPT-1) study , 2003, International journal of STD & AIDS.

[8]  C. Kendall,et al.  Patterns of adherence to antiretrovirals: why adherence has no simple measure. , 2003, AIDS patient care and STDs.

[9]  M. Chesney,et al.  Longitudinal study of mental health and psychosocial predictors of medical treatment adherence in mothers living with HIV disease. , 2003, AIDS patient care and STDs.

[10]  J. Farley,et al.  Assessment of adherence to antiviral therapy in HIV-infected children using the Medication Event Monitoring System, pharmacy refill, provider assessment, caregiver self-report, and appointment keeping. , 2003, Journal of acquired immune deficiency syndromes.

[11]  J. Ziegler,et al.  Adherence issues in children and adolescents receiving highly active antiretroviral therapy , 2003, AIDS care.

[12]  D. Gibb,et al.  Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial , 2003, The Pediatric infectious disease journal.

[13]  D. Murphy,et al.  Factors Associated with Antiretroviral Adherence Among HIV-Infected Women with Children , 2002, Women & health.

[14]  D. Pillay,et al.  Evolution of Antiretroviral Phenotypic and Genotypic Drug Resistance in Antiretroviral-Naive HIV-1-Infected Children Treated with Abacavir/Lamivudine, Zidovudine/Lamivudine or Abacavir/Zidovudine, with or without Nelfinavir (The Penta 5 Trial) , 2001, Antiviral therapy.

[15]  R. Steele,et al.  Adherence to antiretroviral therapy among HIV-positive children: Examination of the role of caregiver health beliefs , 2001, AIDS care.

[16]  A. DeMaria,et al.  Adherence to medication regimens among children with human immunodeficiency virus infection , 2000, The Pediatric infectious disease journal.

[17]  Susan Swindells,et al.  Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.

[18]  M. Chesney,et al.  Factors affecting adherence to antiretroviral therapy. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  R. Berni Canani,et al.  Adherence to antiretroviral therapy in HIV-infected children in Italy. , 1999, AIDS care.

[20]  J. Farley,et al.  Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. , 1999, The Pediatric infectious disease journal.